{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Nuvation Bio, Inc.
Nuvation Bio Hits Day High with 10.48% Surge, Showcases Strong Intraday Performance
Nuvation Bio, Inc. has seen notable stock performance, with significant increases over various time frames, including a 110.87% return over the past year. Despite facing challenges such as negative results in recent quarters and declining profits, the company's market capitalization stands at approximately USD 1,198 million.
Nuvation Bio Hits New 52-Week High of $4.87, Up 67%
Nuvation Bio, Inc. has achieved a new 52-week high, reflecting a strong one-year performance that significantly outpaces the S&P 500. With a market capitalization of USD 1,198 million, the company faces challenges, including negative return on equity and a high debt-to-equity ratio, while pursuing a growth-focused strategy.
Nuvation Bio Hits New 52-Week High of $4.32, Up 43.1%
Nuvation Bio, Inc. has achieved a new 52-week high, reflecting a strong one-year performance that surpasses the S&P 500. With a market capitalization of USD 1,198 million, the company faces challenges in financial metrics, including negative return on equity and a high price-to-book ratio, amidst a competitive biotechnology landscape.
Nuvation Bio Hits Day High with 15.63% Surge in Strong Intraday Performance
Nuvation Bio, Inc. has seen notable stock activity, with a significant increase on September 30, 2025. The company has demonstrated strong weekly and monthly performance, alongside a year-to-date rise. Despite facing challenges with consecutive negative quarterly results, its one-year return reflects resilience in the competitive pharmaceuticals sector.
Nuvation Bio Stock Hits Day Low of $3.00 Amid Price Pressure
Nuvation Bio, Inc. has faced a notable stock decline, reaching an intraday low amid a challenging trading environment. Despite a positive monthly performance, the company's long-term outlook is concerning, with significant declines over five years and ongoing negative quarterly results, raising valuation concerns.
Is Nuvation Bio, Inc. technically bullish or bearish?
As of September 3, 2025, Nuvation Bio, Inc. shows a bullish technical trend with positive momentum indicators, having returned 19.17% year-to-date, outperforming the S&P 500, despite underperforming over longer periods.
Is Nuvation Bio, Inc. overvalued or undervalued?
As of August 5, 2024, Nuvation Bio, Inc. is considered risky due to overvaluation and poor financial metrics, including a Price to Book Value of 2.01, an EV to Sales ratio of 35.57, and a negative ROE of -43.17%, despite a year-to-date return of 19.17% that outperformed the S&P 500.
Is Nuvation Bio, Inc. overvalued or undervalued?
As of August 5, 2024, Nuvation Bio, Inc. is rated as "risky" and overvalued, with concerning financial metrics including a Price to Book Value of 2.01, an EV to EBIT of -1.89, and an ROE of -43.17%, while its year-to-date stock performance has declined by 23.68%, underperforming the S&P 500's 2.44% return.
Is Nuvation Bio, Inc. technically bullish or bearish?
As of June 13, 2025, the technical trend is mildly bearish, with daily moving averages indicating bearish momentum, while mixed signals from the MACD and Bollinger Bands suggest a lack of strong bullish momentum and underperformance against the S&P 500.
What does Nuvation Bio, Inc. do?
Nuvation Bio, Inc. is a micro-cap biotechnology company focused on opportunities in the pharmaceuticals sector, with recent net sales of $3 million and a net loss of $53 million. The company has a market cap of $581.85 million and does not currently pay dividends.
How big is Nuvation Bio, Inc.?
As of Jun 18, Nuvation Bio, Inc. has a market capitalization of 581.85 million, categorizing it as a Micro Cap company, with net sales of 10.96 million and a net profit of -606.39 million over the latest four quarters.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
